ESMO 2017 | ICON8: Outcome in progression-free survival for weekly-dose paclitaxel in first-line ovarian cancer
Jonathan Ledermann, BSc, MD, FRCP, from the University College London, London, UK, provides an overview of ICON8 (NCT01654146), a UK led international trial, through the gynecological cancer intergroup. The study evaluates the weekly dose of paclitaxel in the first-line treatment of ovarian cancer. This study was implemented in different populations after results from the Japanese-led study in 2009 found a weekly dose of paclitaxel to show significant improvements in progression-free survival and overall survival. Results from the UK led ICON8, European-led MITO-7 (NCT00660842) trials, both displayed contradicting results for weekly doses of paclitaxel compared to the Japanese-led trial. Prof. Ledermann, mentions the GOG-0263 trial (NCT01101451) also comparing a weekly dose of paclitaxel against the current standard, three-week dose. In this trial, 85 percent of patients were administered bevacizumab. Again, results do not match the outcome of the Japanese-led trial. Once the data in different settings are corroborated, the standard of care can continue to evolve. Recorded at the ESMO 2017 Congress in Madrid, Spain.
Get great new content delivered to your inboxSign up